Margaret Macro

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +10

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial

Jean‐Paul Fermand, Philippe Ravaud, Sylvie Chevret et al. · Blood · 1998 · 539 citations

Medicine, Hematology, Oncology +17